retatrutide phase 2 trial obesity nejm 2023 Michael Weintraub, MD on X: "Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight obesity #retatrutide #weight #glp1 #nejm

10.3389/fphys.2018.01622 Summary Keywords dipeptidyl peptidase-4, glucagon-like peptide-1, incretin, peptide degradation, therapy, type 2 diabetes Citation Deacon CF (2019) Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

up to 10 mM in liver the most abundant non-protein thiol in mammalian cells Redox forms: Reduced GSH (active) and oxidised GSSG

Sermorelin tends to produce smaller GH releases than ipamorelin

Most published studies are small, involve patients affected by obesity and/or T2DM, and may therefore not be fully generalizable to the broader PsO/PsA population